Organon inks $103M deal for pertuzumab and denosumab biosimilars

Beth Snyder Bulik

Senior Editor

Organon is looking to boost its biosimilar portfolio with two well-known brand copies in development by Shanghai-based Henlius Biotech.

The women’s health pharma is paying $73 million upfront, plus up to $30 million in 2022 milestone payments, for the pertuzumab biosimilar to Roche’s Genentech’s breast cancer drug Perjeta and the denosumab biosimilar to Amgen’s Prolia for osteoporosis and Xgeva for bone problem prevention in cancer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Organon inks $103M deal for pertuzumab and denosumab biosimilars

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence

Organon inks $103M deal for per­tuzum­ab and deno­sum­ab biosim­i­lars

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Organon inks $103M deal for pertuzumab and denosumab biosimilars

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence